金城医药终止与Giskit意向性合作项目

Core Viewpoint - Jincheng Pharmaceutical has decided to terminate its intended cooperation project with Giskit Pharma B.V. due to insufficient progress in negotiations and lack of consensus on key issues [1] Summary by Relevant Sections Cooperation Agreement - In August 2024, Jincheng Pharmaceutical and Giskit began negotiations for exclusive commercialization rights in China for Giskit's drug ExEm Foam, which evaluates tubal patency in women with infertility [1] - In September 2024, both parties agreed to extend exclusive negotiations until November 15, 2024, to reach a final agreement [1] - On November 18, 2024, Jincheng disclosed that negotiations on key terms for exclusive distribution were still ongoing after the expiration of the exclusivity period [1] Decision to Terminate - Jincheng Pharmaceutical stated that the cooperation framework agreement was only a preliminary arrangement, and no formal cooperation agreement was signed [1] - The negotiations did not progress as expected, and no substantial advancements were made regarding the cooperation project [1] - After careful consideration of its development strategy and operational circumstances, the company decided to terminate the intended cooperation project [1]